fbpx

Locoregional Stomach Cancer

Gastric Adenocarcinoma

Female, 39 years

Patient Internal ID: 03598079

ICD-10 code

C16.2 Malignant Neoplasm of Body of Stomach

Diagnosis (Incl. Metastases/Stage) and Year

December 2019
Gastric Adenocarcinoma of Proximal Part ypT4aN2M0 LVI R0 G3 HER2(-). Disease progression in January 2021, Metastasis in the Ovaries.

Previous Treatment

Chemotherapy (FLOT scheme), Surgery (Gastrectomy), HIPEC (Cisplatin), Chemotherapy (FOLFOX scheme).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~14 months from diagnosis for patients who received Gastric Resection and Postoperative Adjuvant Therapy.

Treatment Provided

Autologous DCV (7 doses) over a period of 6 months.

Patient Survival/Condition and Year
Date of Review: 02/12/2023

The patient has survived for 20 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy, Surgery and HIPEC, has extended patient survival by an estimate of around 6 months.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.

Ok